Wuxi Biologics (Cayman) (2269N) Stock Statistics & Valuation Metrics

Wuxi Biologics (Cayman) has a market cap or net worth of $361.21B. The enterprise value is $123.38K.

Wuxi Biologics (Cayman) has 4,143,562,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.26%.

The current PE Ratio of Wuxi Biologics (Cayman) is 28.3. Wuxi Biologics (Cayman)’s PEG ratio is 0.53.

In the last 12 months, Wuxi Biologics (Cayman) had revenue of 21.79B and earned 4.91B in profits. Earnings per share was 1.19.

In the last 12 months, operating cash flow was 6.41B and capital expenditures -3.71B, giving a free cash flow of 2.70B billion.

Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―

Wuxi Biologics (Cayman) upcoming earnings date is Aug 26, 2026, TBA (Confirmed).

Wuxi Biologics (Cayman) as a current ratio of 3.14, with Debt / Equity ratio of 6.57%

In the past 12 months, Wuxi Biologics (Cayman) has paid 1.52B in taxes.

Wuxi Biologics (Cayman) EV to EBITDA ratio is 14.30, with an EV/FCF ratio of 40.48.

Wuxi Biologics (Cayman) has $15.74B in cash and marketable securities with $3.11B in debt, giving a net cash position of $12.64B billion.

Gross margin is 45.98%, with operating margin of 30.47%, and net profit margin of 22.53%.

The average price target for Wuxi Biologics (Cayman) is ―, which is 11.43% higher than the current price. The consensus rating is ―